MediWound (NASDAQ:MDWD – Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, November 26th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
MediWound Trading Down 2.3 %
Shares of NASDAQ MDWD opened at $15.64 on Tuesday. The firm has a market capitalization of $168.76 million, a price-to-earnings ratio of -7.41 and a beta of 0.83. MediWound has a one year low of $8.22 and a one year high of $24.00. The business has a fifty day simple moving average of $17.31 and a 200 day simple moving average of $17.47.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. StockNews.com raised shares of MediWound to a “sell” rating in a report on Monday, August 5th. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of MediWound in a research note on Friday, October 11th.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also
- Five stocks we like better than MediWound
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Investing in Travel Stocks Benefits
- Applied Materials Market Capitulates: Now is the Time to Buy
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.